A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma

  • Authors:
    • Qi Zheng
    • Yichao Zheng
    • Jing Chen
    • Jia You
    • Yueyong Zhu
    • Yurui Liu
    • Jia Ji Jiang
  • View Affiliations

  • Published online on: January 17, 2017     https://doi.org/10.3892/or.2017.5381
  • Pages: 1716-1724
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Stem cells and cancer cells express a common subset of antigens called oncofetal antigens. Theoretically, vaccination with stem cells is effective at boosting the preexisting anticancer immune response. Herein we describe the efficacy of two stem cell-based vaccines in the prophylaxis and treatment of subcutaneous hepatic tumors transplanted into mice. C57BL/6j mice were vaccinated weekly with either hepatic stem cells (HSCs) or embryonic stem cells (ESCs) for three weeks, followed by a subcutaneous challenge with Hepa 1-6 cells at one week (group 1) or four weeks (group 2) after vaccination. No tumor formation was observed in HSC-vaccinated mice when challenged within one week after vaccination (group 1), but tumors formed in 10% of mice in the ESC-vaccinated group and in 60% of mice in the unvaccinated group. When the long-term memory response was examined (group 2), only 10% of HSC-vaccinated mice and 20% of ESC-vaccinated mice developed macroscopic hepatocarcinomas compared to 60% of the unvaccinated mice. Besides their function as prophylactic vaccines, administration of either HSC or ESC could be a potential treatment for cancer. In mice with subcutaneous hepatocarcinomas, complete clearance of tumor burden was observed in 80% of mice receiving HSC vaccination, but 40% of ESC-vaccinated mice presented with tumors that did not increase in size over time. These data support that HSC is a superior vaccine candidate for durable antitumor protection in this hepatocarcinoma model.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 37 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zheng Q, Zheng Y, Chen J, You J, Zhu Y, Liu Y and Jiang JJ: A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma. Oncol Rep 37: 1716-1724, 2017
APA
Zheng, Q., Zheng, Y., Chen, J., You, J., Zhu, Y., Liu, Y., & Jiang, J.J. (2017). A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma. Oncology Reports, 37, 1716-1724. https://doi.org/10.3892/or.2017.5381
MLA
Zheng, Q., Zheng, Y., Chen, J., You, J., Zhu, Y., Liu, Y., Jiang, J. J."A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma". Oncology Reports 37.3 (2017): 1716-1724.
Chicago
Zheng, Q., Zheng, Y., Chen, J., You, J., Zhu, Y., Liu, Y., Jiang, J. J."A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma". Oncology Reports 37, no. 3 (2017): 1716-1724. https://doi.org/10.3892/or.2017.5381